哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-080 哈尔滨誉衡药业股份有限公司 关于使用闲置自有资金进行委托理财的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025年4月24日，哈尔滨誉衡药业股份有限公司（以下简称"公司"）第七届 董事会第三次会议审议通过了《关于使用闲置自有资金进行委托理财的议案》。 同意公司及纳入合并报表范围内的子公司使用不超过人民币39,000万元自有闲 置资金额度在金融机构购买中等或中等以下风险的委托理财产品，在上述投资额 度内，各投资主体资金可以滚动使用，委托理财期限自董事会审议通过之日起一 年内有效，并授权公司经理层负责具体组织实施。具体情况详见2025年4月26日 公司披露于《中国证券报》、《证券时报》及巨潮资讯网http://www.cninfo.com.cn （以下简称"指定媒体"）的《关于使用闲置自有资金进行委托理财的公告》。 2025年10月13日，公司第七届董事会第五次会议审议通过了《关于调整使用 自有闲置资金进行委托理财额度的议案》。同意将公司及纳入合并报 ...

证券日报网讯11月28日，誉衡药业（002437）在互动平台回答投资者提问时表示，安脑丸是一款处方 药，主要应用场景在医院，实体药店只有部分省份在售，如陕西、湖北等。 ...

（文章来源：证券日报） 证券日报网讯誉衡药业11月26日在互动平台回答投资者提问时表示，截至2025年11月20日，公司股东人 数为10.39万户。 ...

Core Viewpoint - The conference focused on the efficient transformation and international development of traditional Chinese medicine (TCM) technology, highlighting the importance of mindset over technology in the digital transformation of TCM [2][3]. Group 1: Digital Transformation Challenges - The primary obstacle in the digital transformation of TCM is not technology but rather the mindset of individuals within the industry [2]. - The integration of TCM and Western medicine is possible in practice, despite theoretical challenges, emphasizing the need for acceptance and recognition of both approaches [2][3]. Group 2: Key Paths for TCM Research - TCM research should center around "human experience," with digital tools aimed at modernizing this experience [3]. - Two critical paths for achieving this include establishing standards and databases to convert classical texts into usable modern resources, and utilizing digitalization to promote TCM accessibility [3]. Group 3: Internationalization of TCM - The successful internationalization of TCM relies on effective communication and cultural exchange, particularly in aligning with scientific standards for Western markets and leveraging TCM's strengths in developing countries [3]. - The cultivation of interdisciplinary talents who understand both TCM and Western medicine is essential for overcoming barriers in the digital transformation process [3]. Group 4: Conclusion on Digitalization - Digitalization is a vital tool for TCM, but breaking down conceptual barriers and achieving ideological integration is crucial for technology to truly empower the development of TCM [3].

Core Viewpoint - Harbin Yuheng Pharmaceutical Co., Ltd. announced that its board member and general manager, Guo Leifeng, along with his concerted actor, Tibet Yupin Enterprise Management Partnership, successfully acquired a total of 25 million shares through a judicial auction, representing 1.12% of the company's total share capital [1][2]. Group 1: Shareholding Details - Yu Heng International Investments Corporation holds 56,778,123 shares, and Oriental Keystone Investment Limited holds 42,900,000 shares, which were publicly auctioned on Taobao from November 20 to November 21, 2025 [1]. - Guo Leifeng, as the general partner and executive partner of Tibet Yupin, is considered a concerted actor in this acquisition [2]. Group 2: Impact and Regulations - The judicial auction will not affect the company's normal production and operation activities, nor will it lead to a non-compliance in the company's shareholding distribution for listing requirements [2]. - Following the completion of the transfer, Guo Leifeng and Tibet Yupin are prohibited from reducing their shareholdings within six months [2].

Core Points - Yu Heng International Investments Corporation and Oriental Keystone Investment Limited are auctioning a total of 99,678,123 shares of Yu Heng Pharmaceutical on a judicial auction platform from November 20 to November 21, 2025 [2] - The auction results show that the company's director and general manager, Guo Leifeng, along with his concerted action partner, Tibet Yupan Enterprise Management Partnership, successfully acquired 25 million shares, representing 1.12% of the company's total share capital [2]

Group 1 - Central Plaza received a warning letter from Jiangsu Securities Regulatory Commission due to failure to timely disclose significant litigation progress and accounting treatment, affecting the accuracy of the 2025 semi-annual report [4] - Jiaron Technology announced a stock suspension as it plans a major asset restructuring through share issuance and fundraising, with the suspension expected to last no more than 10 trading days [5] - Maiwei Co. is undergoing a debt restructuring involving accounts receivable totaling 371 million yuan, with an estimated loss of 85.465 million yuan, aimed at accelerating cash flow recovery and reducing receivables risk [6] Group 2 - New World plans to use up to 850 million yuan of idle fundraising to purchase financial products or deposits, having previously used 575 million yuan for similar purposes [7] - Huyou Pharmaceutical's HYP-6589 tablet clinical trial application for treating advanced non-small cell lung cancer has been accepted by the National Medical Products Administration [8] - Sunshine Nuohuo's lawsuit against Hengsheng Pharmaceutical has entered the second instance, with the original claim amounting to 20 million yuan and a counterclaim of 740.73 thousand yuan [9] Group 3 - Guolian Aquatic received a warning letter from Guangdong Securities Regulatory Commission for non-operating fund occupation by its controlling shareholder, with a total borrowing of 7.8 million yuan [10] - Renfu Pharmaceutical's application for the marketing authorization of Dexmethylphenidate capsules has been accepted, targeting ADHD treatment [11] - Jindi Co. signed a strategic cooperation letter with Dongpei Co. to explore collaboration on humanoid robot harmonic reducer assemblies [12] Group 4 - Yuyuan Co. repurchased 1 million A-shares for a total payment of approximately 5.386 million yuan, as part of a broader repurchase plan of 200-300 million yuan [13] - Yuheng Pharmaceutical's executives increased their holdings by 1.12% through a judicial auction, acquiring 25 million shares [14] - Zhonghuan Co. shareholders plan to reduce their holdings by 1.02% and 0.24% respectively, citing personal funding needs [15] Group 5 - Huibo Co. won a contract for the Iraq NaftKhana oilfield restoration project worth approximately 1.596 billion yuan, expected to significantly impact 2026-2027 performance [17] - Dajin Heavy Industry's subsidiary signed a contract for a European offshore wind farm project valued at approximately 1.339 billion yuan, representing 35.41% of the company's 2024 audited revenue [18]

Group 1 - Daikin Heavy Industries' subsidiary signed a contract worth approximately 1.339 billion yuan for an offshore wind farm project in Europe, accounting for 35.41% of the company's audited revenue for 2024 [1] Group 2 - Zhaoyi Innovation announced that several board members and senior management plan to reduce their holdings by a total of 249,000 shares, due to personal financial needs, with the reduction period set from December 15, 2025, to March 14, 2026 [2] Group 3 - Jushi Chemical received a notice from the China Securities Regulatory Commission regarding an investigation for suspected violations of information disclosure laws, while the company's operations continue normally [3][6] Group 4 - Chaozhuo Aerospace announced a stock suspension due to major matters being planned by its controlling shareholders, which may lead to a change in control [4] Group 5 - Heng Rui Medicine received approval for clinical trials of SHR-1139 injection, a biopharmaceutical with no similar products approved for sale domestically or internationally, with a cumulative R&D investment of approximately 100.13 million yuan [5] Group 6 - Huayou Pharmaceutical's HYP-6589 tablet for treating advanced non-small cell lung cancer received a clinical trial application acceptance notice, with no similar products approved for sale [8] Group 7 - Renfu Pharmaceutical's application for the marketing license of Dexamethasone L-amphetamine capsules was accepted, aimed at treating ADHD, with a cumulative R&D investment of approximately 90 million yuan [10] Group 8 - Huibo Group won a bid for a 1.596 billion yuan project for the restoration of an oil field in Iraq [10]

Regulatory Actions - Haosai is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure, but the company states that its operations remain normal and the investigation will not significantly impact management [2] - Central Plaza and its executives received a warning letter from the Jiangsu Securities Regulatory Bureau for failing to timely disclose significant litigation progress, which led to inaccurate financial reporting [3] - Guolian Aquatic received a warning letter from the Guangdong Securities Regulatory Bureau for non-operating fund occupation by its controlling shareholder, which was not disclosed in a timely manner [9] Corporate Actions - Jiarong Technology is planning a major asset restructuring and has suspended trading of its shares, expected to last no more than 10 trading days [4] - Maiwei Co. announced a debt restructuring totaling 371 million yuan, with an expected loss of 85.465 million yuan, aimed at improving cash flow and reducing receivables risk [5] - New World plans to use up to 850 million yuan of idle fundraising to purchase financial products or deposits, with a total of 575 million yuan already invested in such products [6] Legal Matters - Sunshine Nuohuo's lawsuit against Hengsheng Pharmaceutical has entered the second instance, with the original claim amounting to 20 million yuan and a counterclaim of 7.4073 million yuan [8] Product Development - Huyou Pharmaceutical's HYP-6589 tablet has received acceptance for clinical trial applications for treating advanced non-small cell lung cancer [7] - Renfu Pharmaceutical's application for the marketing license of a new ADHD treatment has been accepted, with no similar products currently available in the domestic market [10] Strategic Partnerships - Jindi Co. signed a strategic cooperation letter of intent with Dongpei Co. to explore collaboration on humanoid robot harmonic reducer assemblies and key components [11] Share Buybacks and Holdings - Yuyuan Co. has repurchased 1 million A-shares for a total of approximately 5.3864 million yuan as part of a buyback plan [12] - Yuheng Pharmaceutical's executives increased their holdings by 1.12%, acquiring a total of 25 million shares [13] Major Contracts - Huayou Huibo has been awarded a contract worth 225 million USD for the Iraq NaftKhana oilfield project, which is expected to significantly impact future earnings [16] - Dajin Heavy Industry's subsidiary signed a contract worth approximately 1.339 billion yuan for a European offshore wind farm project, representing 35.41% of the company's expected annual revenue [17]

Core Viewpoint - Yu Heng International Investments Corporation and Oriental Keystone Investment Limited are set to publicly auction a total of 99.68 million shares of Yu Heng Pharmaceutical on Taobao from November 20 to November 21, 2025, which may impact the company's stock structure and ownership dynamics [1] Group 1 - Yu Heng International Investments Corporation holds 56.7781 million shares, while Oriental Keystone Investment Limited holds 42.9 million shares, both of which will be auctioned [1] - On November 21, 2025, it was reported that Guo Leifeng, the company's director, general manager, and financial officer, along with his concerted party, Tibet Yupan Enterprise Management Partnership (Limited Partnership), successfully bid for a total of 25 million shares, representing 1.12% of the company's total equity [1]